Sava Infond D.O.O. Sarepta Therapeutics, Inc. Transaction History
Sava Infond D.O.O.
- $524 Billion
- Q1 2025
A detailed history of Sava Infond D.O.O. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Sava Infond D.O.O. holds 4,500 shares of SRPT stock, worth $94,230. This represents 0.05% of its overall portfolio holdings.
Number of Shares
4,500
Previous 3,000
50.0%
Holding current value
$94,230
Previous $365 Million
21.27%
% of portfolio
0.05%
Previous 0.06%
Shares
2 transactions
Others Institutions Holding SRPT
# of Institutions
508Shares Held
88.9MCall Options Held
1.39MPut Options Held
1.13M-
Black Rock Inc. New York, NY10.3MShares$216 Million0.04% of portfolio
-
Capital International Investors Los Angeles, CA9.06MShares$190 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.03MShares$189 Million0.01% of portfolio
-
State Street Corp Boston, MA4.07MShares$85.2 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X03.36MShares$70.5 Million0.12% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.83B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...